Consensus Vor Biopharma Inc.

Equities

VOR

US9290331084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.69 ^USD	-0.59%		-1.17%	-24.89%

Mar. 21	Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	MT
Mar. 21	Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	MT

Evolution of the average Target Price on Vor Biopharma Inc.

Price target over the last 5 years

History of analyst recommendation changes

a5f8f6dd5493caf5d9ca22e4bb7e2e.nY51JXY-JMDdTGPn-OFdiScEhhJ4AZapA-YU-aJHpzU.pMQ4bEVUQ6SILjKGkJQOsEN-_EAJMvDlRLRhzOcE91jf4kFJH1VLiLceDA~49de4cb3be1c589eaadf24a8cfd00042

Analyst Recommendations on Vor Biopharma Inc.

Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	Mar. 21	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	Mar. 21	MT
Wedbush Cuts Vor Biopharma's Price Target to $11 From $18, Keeps Outperform Rating	23-08-11	MT
JonesTrading Starts Vor Biopharma at Buy With $18 Price Target	23-05-16	MT
Barclays Adjusts Price Target on Vor Biopharma to $10 From $15, Maintains Overweight Rating	23-03-24	MT
HC Wainwright Adjusts Price Target on Vor Biopharma to $17.50 From $20, Maintains Buy Rating	23-03-24	MT
Stifel Adjusts Price Target on Vor Biopharma to $16 From $17, Maintains Buy Rating	23-03-24	MT
Baird Adjusts Vor Biopharma Price Target to $22 From $38, Maintains Outperform Rating	23-03-24	MT
JMP Securities Adjusts Price Target on Vor Biopharma to $12 From $15, Maintains Market Outperform Rating	23-01-19	MT
Oppenheimer Adjusts Vor Biopharma Price Target to $18 From $27, Maintains Outperform Rating	22-11-14	MT
Stifel Nicolaus Adjusts Vor Biopharma Price Target to $17 From $21, Maintains Buy Rating	22-11-11	MT
Barclays Adjusts Price Target on Vor Biopharma to $15 From $26, Maintains Overweight Rating	22-11-11	MT
HC Wainwright Adjusts Vor Biopharma's Price Target to $20 From $26, Keeps Buy Rating	22-08-15	MT
Stifel Adjusts Vor Biopharma's Price Target to $21 from $24, Keeps Buy Rating	22-08-12	MT
Wedbush Starts Vor Biopharma at Outperform With $18 Price Target	22-07-26	MT
Goldman Sachs Adjusts Price Target for Vor Biopharma to $4 From $6, Reiterates Neutral Rating	22-05-24	MT
JMP Securities Adjusts Vor Biopharma's Price Target to $15 From $30, Maintains Market Outperform Rating	22-05-13	MT
Goldman Sachs Starts Vor Biopharma at Neutral With $6 Price Target	22-04-27	MT
Barclays Adjusts Vor Biopharma's Price Target to $26 From $56; Overweight Rating Kept	22-03-21	MT
JMP Securities Adjusts Vor Biopharma's Price Target to $30 From $40, Keeps Market Outperform Rating	22-03-16	MT
Stifel Nicolaus Lowers Price Target for Vor Biopharma to $29 From $50, Maintains Buy Rating	22-03-15	MT
Oppenheimer Adjusts Vor Biopharma Price Target to $27 From $30, Maintains Outperform Rating	22-03-15	MT
B. Riley Lowers Vor Biopharma's Price Target to $46 from $60 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
HC Wainwright Initiates Vor Biopharma at Buy With $26 Price Target	21-12-17	MT
Baird Starts Vor Biopharma at Outperform With $38 Price Target	21-12-03	MT